KR101833578B1 - 아프레피탄트 l-프롤린 조성물 및 공결정 - Google Patents

아프레피탄트 l-프롤린 조성물 및 공결정 Download PDF

Info

Publication number
KR101833578B1
KR101833578B1 KR1020137010228A KR20137010228A KR101833578B1 KR 101833578 B1 KR101833578 B1 KR 101833578B1 KR 1020137010228 A KR1020137010228 A KR 1020137010228A KR 20137010228 A KR20137010228 A KR 20137010228A KR 101833578 B1 KR101833578 B1 KR 101833578B1
Authority
KR
South Korea
Prior art keywords
proline
crystals
aprepitant
composition
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137010228A
Other languages
English (en)
Korean (ko)
Other versions
KR20140040671A (ko
Inventor
조앤 홀란드
크리스토퍼 프램튼
앨런 콜튼
다니엘 구딩
Original Assignee
누포믹스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 누포믹스 리미티드 filed Critical 누포믹스 리미티드
Publication of KR20140040671A publication Critical patent/KR20140040671A/ko
Application granted granted Critical
Publication of KR101833578B1 publication Critical patent/KR101833578B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020137010228A 2010-09-23 2011-09-23 아프레피탄트 l-프롤린 조성물 및 공결정 Active KR101833578B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38574410P 2010-09-23 2010-09-23
US61/385,744 2010-09-23
US201161439654P 2011-02-04 2011-02-04
US61/439,654 2011-02-04
US201161498214P 2011-06-17 2011-06-17
US61/498,214 2011-06-17
PCT/IB2011/054210 WO2012038937A1 (en) 2010-09-23 2011-09-23 Aprepitant l-proline composition and cocrystal

Publications (2)

Publication Number Publication Date
KR20140040671A KR20140040671A (ko) 2014-04-03
KR101833578B1 true KR101833578B1 (ko) 2018-02-28

Family

ID=44907915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137010228A Active KR101833578B1 (ko) 2010-09-23 2011-09-23 아프레피탄트 l-프롤린 조성물 및 공결정

Country Status (13)

Country Link
US (1) US9029369B2 (https=)
EP (1) EP2618828B1 (https=)
JP (1) JP5997162B2 (https=)
KR (1) KR101833578B1 (https=)
CN (1) CN103221049B (https=)
AR (1) AR083095A1 (https=)
AU (1) AU2011306391B2 (https=)
BR (1) BR112013006651A2 (https=)
CA (1) CA2846460C (https=)
ES (1) ES2616752T3 (https=)
IL (1) IL225443A0 (https=)
TW (1) TWI540131B (https=)
WO (1) WO2012038937A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029369B2 (en) 2010-09-23 2015-05-12 Nuformix Limited Aprepitant L-proline composition and cocrystal
CA2892832C (en) 2011-11-25 2020-04-14 Nuformix Technologies Limited Aprepitant l-proline solvates - compositions and cocrystals
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
WO2015101596A2 (en) * 2013-12-30 2015-07-09 Oncoprevent Gmbh Neurokinin-1 receptor antagonists for use in a method of prevention of cancer
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE
CN116283947A (zh) * 2023-02-07 2023-06-23 成都医学院 一种阿瑞匹坦共晶及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078161A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20090209541A1 (en) * 2006-06-16 2009-08-20 Dr. Reddy's Laboratories Ltd. Aprepitant compositions
WO2009108828A2 (en) * 2008-02-27 2009-09-03 Dr. Reddy's Laboratories Ltd. Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
US9029369B2 (en) 2010-09-23 2015-05-12 Nuformix Limited Aprepitant L-proline composition and cocrystal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078161A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Also Published As

Publication number Publication date
AU2011306391A1 (en) 2013-04-11
CA2846460A1 (en) 2012-03-29
JP2013537901A (ja) 2013-10-07
ES2616752T3 (es) 2017-06-14
EP2618828B1 (en) 2016-11-23
HK1187554A1 (zh) 2014-04-11
KR20140040671A (ko) 2014-04-03
AR083095A1 (es) 2013-01-30
WO2012038937A1 (en) 2012-03-29
US20130252949A1 (en) 2013-09-26
TWI540131B (zh) 2016-07-01
JP5997162B2 (ja) 2016-09-28
US9029369B2 (en) 2015-05-12
CN103221049B (zh) 2015-11-25
TW201217366A (en) 2012-05-01
AU2011306391B2 (en) 2016-12-15
EP2618828A1 (en) 2013-07-31
CA2846460C (en) 2019-01-08
IL225443A0 (en) 2013-06-27
CN103221049A (zh) 2013-07-24
BR112013006651A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
KR101833578B1 (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
US8779146B2 (en) Cilostazol cocrystals and compositions
US9532993B2 (en) Aprepitant L-proline solvates—compositions and cocrystals
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
US8871793B2 (en) Metaxalone cocrystals
AU2022384750B2 (en) Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1 s)-1 -methyl-2- (methyloxy)ethyl]oxy)-n-(5-methylpyrazin-2-yl)benzamide
HK1187554B (en) Aprepitant l-proline composition and cocrystal
IL324898A (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinozolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
JP2023535846A (ja) 含窒素複素環化合物の塩及びその塩の固体形態、医薬組成物並びに用途
HK1178519B (en) Metaxalone cocrystals

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130422

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160923

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170814

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20180102

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180222

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210209

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220215

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230208

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240206

Start annual number: 7

End annual number: 7